{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Parkinson\u2019s disease", "alpha synuclein", "mitochondrial dysfunction", "natural products", "neurodegeneration", "neuroinflammation", "oxidative stress"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38256144", "DateCompleted": {"Year": "2024", "Month": "01", "Day": "24"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "01"}, "Article": {"Language": ["eng"], "ELocationID": ["1071", "10.3390/ijms25021071"], "ArticleDate": [{"Year": "2024", "Month": "01", "Day": "15"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "2", "PubDate": {"Year": "2024", "Month": "Jan", "Day": "15"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach.", "Abstract": {"AbstractText": ["As the global population ages, the prevalence of Parkinson's disease (PD) is steadily on the rise. PD demonstrates chronic and progressive characteristics, and many cases can transition into dementia. This increases societal and economic burdens, emphasizing the need to find effective treatments. Among the widely recognized causes of PD is the abnormal accumulation of proteins, and autophagy dysfunction accelerates this accumulation. The resultant Lewy bodies are also commonly found in Alzheimer's disease patients, suggesting an increased potential for the onset of dementia. Additionally, the production of free radicals due to mitochondrial dysfunction contributes to neuronal damage and degeneration. The activation of astrocytes and the M1 phenotype of microglia promote damage to dopamine neurons. The drugs currently used for PD only delay the clinical progression and exacerbation of the disease without targeting its root cause, and come with various side effects. Thus, there is a demand for treatments with fewer side effects, with much potential offered by natural products. In this study, we reviewed a total of 14 articles related to herbal medicines and natural products and investigated their relevance to possible PD treatment. The results showed that the reviewed herbal medicines and natural products are effective against lysosomal disorder, mitochondrial dysfunction, and inflammation, key mechanisms underlying PD. Therefore, natural products and herbal medicines can reduce neurotoxicity and might improve both motor and non-motor symptoms associated with PD. Furthermore, these products, with their multi-target effects, enhance bioavailability, inhibit antibiotic resistance, and might additionally eliminate side effects, making them good alternative therapies for PD treatment."]}, "AuthorList": [{"Identifier": ["0009-0003-6213-117X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "So", "ForeName": "Yu-Jin", "Initials": "YJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "Lee", "ForeName": "Jae-Ung", "Initials": "JU"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "Yang", "ForeName": "Ga-Seung", "Initials": "GS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "Yang", "ForeName": "Gabsik", "Initials": "G"}, {"Identifier": ["0000-0001-5394-0280"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "Kim", "ForeName": "Sung-Wook", "Initials": "SW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}, {"Identifier": [], "Affiliation": "Da CaPo Co., Ltd., 303 Cheonjam-ro, Wansan-gu, Jeonju-si 55069, Jeollabuk-do, Republic of Korea."}], "LastName": "Lee", "ForeName": "Jun-Ho", "Initials": "JH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Korean Medicine, Woosuk University, Jeonju-si 54986, Jeollabuk-do, Republic of Korea."}], "LastName": "Kim", "ForeName": "Jong-Uk", "Initials": "JU"}], "GrantList": [{"GrantID": "2021R1A2C1012846", "Agency": "National Research Foundation of Korea", "Country": ""}, {"GrantID": "NRF-2021R1I1A1A01059706", "Agency": "National Research Foundation of Korea", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Parkinson Disease"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": [], "DescriptorName": "Mitochondrial Diseases"}, {"QualifierName": [], "DescriptorName": "Plant Extracts"}], "CoiStatement": "Author Jun-Ho Lee was employed by the company Da CaPo Co. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Cho K.h. Korean Medicine Clinical Practice Guideline for Parkinson\u2019s Disease. National Institute for Korean Medicine Development; Seoul, Republic of Korea: 2021."}, {"Citation": "Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46:292\u2013300. doi: 10.1159/000445751.", "ArticleIdList": ["10.1159/000445751", "27105081"]}, {"Citation": "Abbas M.M., Xu Z., Tan L.C.S. Epidemiology of Parkinson\u2019s Disease\u2014East Versus. West. Mov. Disord. Clin. Pract. 2018;5:14\u201328. doi: 10.1002/mdc3.12568.", "ArticleIdList": ["10.1002/mdc3.12568", "PMC6174379", "30363342"]}, {"Citation": "Jerry M., Arcona S., McMorrow D., Schwartz H., Princic N., Sasane R. Work Loss and Direct and Indirect Costs Associated with Parkinson\u2019s Disease. Clin. Outcomes Res. 2023;15:309\u2013319. doi: 10.2147/CEOR.S398509.", "ArticleIdList": ["10.2147/CEOR.S398509", "PMC10150754", "37138588"]}, {"Citation": "Simon D.K., Tanner C.M., Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin. Geriatr. Med. 2020;36:1\u201312. doi: 10.1016/j.cger.2019.08.002.", "ArticleIdList": ["10.1016/j.cger.2019.08.002", "PMC6905381", "31733690"]}, {"Citation": "Church F.C. Treatment Options for Motor and Non-Motor Symptoms of Parkinson\u2019s Disease. Biomolecules. 2021;11:612. doi: 10.3390/biom11040612.", "ArticleIdList": ["10.3390/biom11040612", "PMC8074325", "33924103"]}, {"Citation": "Kempster P.A., Williams D.R., Selikhova M., Holton J., Revesz T., Lees A.J. Patterns of levodopa response in Parkinson\u2019s disease: A clinico-pathological study. Brain. 2007;130:2123\u20132128. doi: 10.1093/brain/awm142.", "ArticleIdList": ["10.1093/brain/awm142", "17586867"]}, {"Citation": "B\u00e4ckstr\u00f6m D., Gran\u00e5sen G., Domell\u00f6f M.E., Linder J., Jakobson Mo S., Riklund K., Zetterberg H., Blennow K., Forsgren L. Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study. Neurology. 2018;91:e2045\u2013e2056. doi: 10.1212/WNL.0000000000006576.", "ArticleIdList": ["10.1212/WNL.0000000000006576", "PMC6282235", "30381367"]}, {"Citation": "Choi H.G., Lim J.S., Lee Y.K., Sim S., Kim M. Mortality and cause of death in South Korean patients with Parkinson\u2019s disease: A longitudinal follow-up study using a national sample cohort. BMJ Open. 2019;9:e029776. doi: 10.1136/bmjopen-2019-029776.", "ArticleIdList": ["10.1136/bmjopen-2019-029776", "PMC6756321", "31530603"]}, {"Citation": "Rong S., Xu G., Liu B., Sun Y., Snetselaar L.G., Wallace R.B., Li B., Liao J., Bao W. Trends in Mortality From Parkinson Disease in the United States, 1999\u20132019. Neurology. 2021;97:e1986\u2013e1993. doi: 10.1212/WNL.0000000000012826.", "ArticleIdList": ["10.1212/WNL.0000000000012826", "34706971"]}, {"Citation": "Macleod A.D., Taylor K.S., Counsell C.E. Mortality in Parkinson\u2019s disease: A systematic review and meta-analysis. Mov. Disord. 2014;29:1615\u20131622. doi: 10.1002/mds.25898.", "ArticleIdList": ["10.1002/mds.25898", "24821648"]}, {"Citation": "Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management. Lancet Neurol. 2006;5:235\u2013245. doi: 10.1016/S1474-4422(06)70373-8.", "ArticleIdList": ["10.1016/S1474-4422(06)70373-8", "16488379"]}, {"Citation": "Schapira A.H.V., Chaudhuri K.R., Jenner P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 2017;18:435\u2013450. doi: 10.1038/nrn.2017.62.", "ArticleIdList": ["10.1038/nrn.2017.62", "28592904"]}, {"Citation": "Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J. Neurochem. 2016;139((Suppl. S1)):318\u2013324. doi: 10.1111/jnc.13691.", "ArticleIdList": ["10.1111/jnc.13691", "27401947"]}, {"Citation": "Schaeffer E., Postuma R.B., Berg D. Prodromal PD: A new nosological entity. Prog. Brain Res. 2020;252:331\u2013356.", "ArticleIdList": ["32247370"]}, {"Citation": "Crouse J.J., Phillips J.R., Jahanshahi M., Moustafa A.A. Postural instability and falls in Parkinson\u2019s disease. Rev. Neurosci. 2016;27:549\u2013555. doi: 10.1515/revneuro-2016-0002.", "ArticleIdList": ["10.1515/revneuro-2016-0002", "26966928"]}, {"Citation": "Palakurthi B., Burugupally S.P. Postural Instability in Parkinson\u2019s Disease: A Review. Brain Sci. 2019;9:239. doi: 10.3390/brainsci9090239.", "ArticleIdList": ["10.3390/brainsci9090239", "PMC6770017", "31540441"]}, {"Citation": "Schrag A., Ben-Shlomo Y., Quinn N. How common are complications of Parkinson\u2019s disease? J. Neurol. 2002;249:419\u2013423. doi: 10.1007/s004150200032.", "ArticleIdList": ["10.1007/s004150200032", "11967646"]}, {"Citation": "Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson\u2019s disease: Variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003;157:1015\u20131022. doi: 10.1093/aje/kwg068.", "ArticleIdList": ["10.1093/aje/kwg068", "12777365"]}, {"Citation": "Armstrong M.J., Okun M.S. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548\u2013560. doi: 10.1001/jama.2019.22360.", "ArticleIdList": ["10.1001/jama.2019.22360", "32044947"]}, {"Citation": "Marino B.L.B., de Souza L.R., Sousa K.P.A., Ferreira J.V., Padilha E.C., da Silva C., Taft C.A., Hage-Melim L.I.S. Parkinson\u2019s Disease: A Review from Pathophysiology to Treatment. Mini Rev. Med. Chem. 2020;20:754\u2013767. doi: 10.2174/1389557519666191104110908.", "ArticleIdList": ["10.2174/1389557519666191104110908", "31686637"]}, {"Citation": "Weintraub D., Aarsland D., Biundo R., Dobkin R., Goldman J., Lewis S. Management of psychiatric and cognitive complications in Parkinson\u2019s disease. BMJ. 2022;379:e068718. doi: 10.1136/bmj-2021-068718.", "ArticleIdList": ["10.1136/bmj-2021-068718", "36280256"]}, {"Citation": "Yang J.Y., Jin C., Lee J., Lee H.G., Cho S.Y., Park S.U., Jung W.S., Moon S.K., Park J.M., Ko C.N., et al. Patients with Parkinson Disease in a Traditional Korean Medicine Hospital: A Five-Year Audit. Evid. Based Complement. Altern. Med. 2021;2021:6842863. doi: 10.1155/2021/6842863.", "ArticleIdList": ["10.1155/2021/6842863", "PMC7815403", "33505501"]}, {"Citation": "Jun P., Zhao H., Kwon O., Jang J.H. Efficacy of Traditional Herbal Medicine Treatment Based on Pattern Identification for Idiopathic Parkinson\u2019s Disease: A Protocol for Systematic Review and Meta-Analysis. Evid. Based Complement. Altern. Med. 2022;2022:4777849. doi: 10.1155/2022/4777849.", "ArticleIdList": ["10.1155/2022/4777849", "PMC9078772", "35535156"]}, {"Citation": "Bae N., Chung S., Kim H.J., Cha J.W., Oh H., Gu M.Y., Oh M.S., Yang H.O. Neuroprotective effect of modified Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in models of Parkinson\u2019s disease. J. Ethnopharmacol. 2015;159:93\u2013101. doi: 10.1016/j.jep.2014.11.007.", "ArticleIdList": ["10.1016/j.jep.2014.11.007", "25449460"]}, {"Citation": "Calabresi P., Mechelli A., Natale G., Volpicelli-Daley L., Di Lazzaro G., Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176. doi: 10.1038/s41419-023-05672-9.", "ArticleIdList": ["10.1038/s41419-023-05672-9", "PMC9977911", "36859484"]}, {"Citation": "Dagra A., Miller D.R., Lin M., Gopinath A., Shaerzadeh F., Harris S., Sorrentino Z.A., St\u00f8ier J.F., Velasco S., Azar J., et al. \u03b1-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. NPJ Park. Dis. 2021;7:76. doi: 10.1038/s41531-021-00210-w.", "ArticleIdList": ["10.1038/s41531-021-00210-w", "PMC8373893", "34408150"]}, {"Citation": "Srinivasan E., Chandrasekhar G., Chandrasekar P., Anbarasu K., Vickram A.S., Karunakaran R., Rajasekaran R., Srikumar P.S. Alpha-Synuclein Aggregation in Parkinson\u2019s Disease. Front. Med. 2021;8:736978. doi: 10.3389/fmed.2021.736978.", "ArticleIdList": ["10.3389/fmed.2021.736978", "PMC8558257", "34733860"]}, {"Citation": "Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u2013840. doi: 10.1038/42166.", "ArticleIdList": ["10.1038/42166", "9278044"]}, {"Citation": "Breydo L., Wu J.W., Uversky V.N. A-synuclein misfolding and Parkinson\u2019s disease. Biochim. Biophys. Acta. 2012;1822:261\u2013885. doi: 10.1016/j.bbadis.2011.10.002.", "ArticleIdList": ["10.1016/j.bbadis.2011.10.002", "22024360"]}, {"Citation": "Vekrellis K., Xilouri M., Emmanouilidou E., Rideout H.J., Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015\u20131025. doi: 10.1016/S1474-4422(11)70213-7.", "ArticleIdList": ["10.1016/S1474-4422(11)70213-7", "22014436"]}, {"Citation": "Cookson M.R. Alpha-Synuclein and neuronal cell death. Mol. Neurodegener. 2009;4:9. doi: 10.1186/1750-1326-4-9.", "ArticleIdList": ["10.1186/1750-1326-4-9", "PMC2646729", "19193223"]}, {"Citation": "Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57\u201371. doi: 10.1016/j.neuron.2011.08.033.", "ArticleIdList": ["10.1016/j.neuron.2011.08.033", "PMC3204802", "21982369"]}, {"Citation": "Luk K.C., Kehm V., Carroll J., Zhang B., O\u2019Brien P., Trojanowski J.Q., Lee V.M. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949\u2013953. doi: 10.1126/science.1227157.", "ArticleIdList": ["10.1126/science.1227157", "PMC3552321", "23161999"]}, {"Citation": "Olanow C.W., Perl D.P., DeMartino G.N., McNaught K.S. Lewy-body formation is an aggresome-related process: A hypothesis. Lancet Neurol. 2004;3:496\u2013503. doi: 10.1016/S1474-4422(04)00827-0.", "ArticleIdList": ["10.1016/S1474-4422(04)00827-0", "15261611"]}, {"Citation": "Lee H.-J., Ricarte D., Ortiz D., Lee S.-J. Models of multiple system atrophy. Exp. Mol. Med. 2019;51:1\u201310. doi: 10.1038/s12276-019-0346-8.", "ArticleIdList": ["10.1038/s12276-019-0346-8", "PMC6861264", "31740682"]}, {"Citation": "Lee H.-J., Bae E.-J., Lee S.-J. Extracellular \u03b1-synuclein\u2014A novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 2014;10:92\u201398. doi: 10.1038/nrneurol.2013.275.", "ArticleIdList": ["10.1038/nrneurol.2013.275", "24468877"]}, {"Citation": "McCann H., Cartwright H., Halliday G.M. Neuropathology of \u03b1-synuclein propagation and braak hypothesis. Mov. Disord. 2016;31:152\u2013160. doi: 10.1002/mds.26421.", "ArticleIdList": ["10.1002/mds.26421", "26340605"]}, {"Citation": "Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 2010;120:131\u2013143. doi: 10.1007/s00401-010-0711-0.", "ArticleIdList": ["10.1007/s00401-010-0711-0", "PMC2892607", "20563819"]}, {"Citation": "Kefalopoulou Z., Politis M., Piccini P., Mencacci N., Bhatia K., Jahanshahi M., Widner H., Rehncrona S., Brundin P., Bj\u00f6rklund A., et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: Two case reports. JAMA Neurol. 2014;71:83\u201387. doi: 10.1001/jamaneurol.2013.4749.", "ArticleIdList": ["10.1001/jamaneurol.2013.4749", "PMC4235249", "24217017"]}, {"Citation": "Braak H., Del Tredici K., R\u00fcb U., de Vos R.A., Steur E.N.J., Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging. 2003;24:197\u2013211. doi: 10.1016/S0197-4580(02)00065-9.", "ArticleIdList": ["10.1016/S0197-4580(02)00065-9", "12498954"]}, {"Citation": "Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson\u2019s disease. Ann. Neurol. 2008;64:485\u2013491. doi: 10.1002/ana.21541.", "ArticleIdList": ["10.1002/ana.21541", "PMC2605160", "19067353"]}, {"Citation": "Ye H., Robak L.A., Yu M., Cykowski M., Shulman J.M. Genetics and Pathogenesis of Parkinson\u2019s Syndrome. Annu. Rev. Pathol. 2023;18:95\u2013121. doi: 10.1146/annurev-pathmechdis-031521-034145.", "ArticleIdList": ["10.1146/annurev-pathmechdis-031521-034145", "PMC10290758", "36100231"]}, {"Citation": "Tolosa E., Santamaria J., Gaig C., Compta Y. Chapter 14\u2014Nonmotor Aspects of Parkinson\u2019s Disease. In: Schapira A.H.V., Lang A.E.T., Fahn S., editors. Blue Books of Neurology. Butterworth-Heinemann; Oxford, UK: 2010. pp. 229\u2013251."}, {"Citation": "Jellinger K.A. Is Braak staging valid for all types of Parkinson\u2019s disease? J. Neural. Transm. 2019;126:423\u2013431. doi: 10.1007/s00702-018-1898-9.", "ArticleIdList": ["10.1007/s00702-018-1898-9", "29943229"]}, {"Citation": "Horsager J., Andersen K.B., Knudsen K., Skj\u00e6rb\u00e6k C., Fedorova T.D., Okkels N., Schaeffer E., Bonkat S.K., Geday J., Otto M., et al. Brain-first versus body-first Parkinson\u2019s disease: A multimodal imaging case-control study. Brain. 2020;143:3077\u20133088. doi: 10.1093/brain/awaa238.", "ArticleIdList": ["10.1093/brain/awaa238", "32830221"]}, {"Citation": "Ahn E.H., Kang S.S., Liu X., Chen G., Zhang Z., Chandrasekharan B., Alam A.M., Neish A.S., Cao X., Ye K. Initiation of Parkinson\u2019s disease from gut to brain by \u03b4-secretase. Cell Res. 2020;30:70\u201387. doi: 10.1038/s41422-019-0241-9.", "ArticleIdList": ["10.1038/s41422-019-0241-9", "PMC6951265", "31649329"]}, {"Citation": "Klann E.M., Dissanayake U., Gurrala A., Farrer M., Shukla A.W., Ramirez-Zamora A., Mai V., Vedam-Mai V. The Gut-Brain Axis and Its Relation to Parkinson\u2019s Disease: A Review. Front. Aging Neurosci. 2021;13:782082. doi: 10.3389/fnagi.2021.782082.", "ArticleIdList": ["10.3389/fnagi.2021.782082", "PMC8776990", "35069178"]}, {"Citation": "Deng J.H., Zhang H.W., Liu X.L., Deng H.Z., Lin F. Morphological changes in Parkinson\u2019s disease based on magnetic resonance imaging: A mini-review of subcortical structures segmentation and shape analysis. World J. Psychiatry. 2022;12:1356\u20131366. doi: 10.5498/wjp.v12.i12.1356.", "ArticleIdList": ["10.5498/wjp.v12.i12.1356", "PMC9791612", "36579355"]}, {"Citation": "Painous C., Pascual-Diaz S., Mu\u00f1oz-Moreno E., S\u00e1nchez V., Pariente J.C., Prats-Galino A., Soto M., Fern\u00e1ndez M., P\u00e9rez-Soriano A., Camara A., et al. Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: A pilot study. Eur. Radiol. 2023;33:4540\u20134551. doi: 10.1007/s00330-023-09435-0.", "ArticleIdList": ["10.1007/s00330-023-09435-0", "PMC10290009", "36773046"]}, {"Citation": "Kuzkina A., R\u00f6\u00dfle J., Seger A., Panzer C., Kohl A., Maltese V., Musacchio T., Blaschke S.J., Tamg\u00fcney G., Kaulitz S., et al. Combining skin and olfactory \u03b1-synuclein seed amplification assays (SAA)-towards biomarker-driven phenotyping in synucleinopathies. NPJ Park. Dis. 2023;9:79. doi: 10.1038/s41531-023-00519-8.", "ArticleIdList": ["10.1038/s41531-023-00519-8", "PMC10226020", "37248217"]}, {"Citation": "Kuzkina A., Bargar C., Schmitt D., R\u00f6\u00dfle J., Wang W., Schubert A.L., Tatsuoka C., Gunzler S.A., Zou W.Q., Volkmann J., et al. Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: A two-laboratory study. NPJ Park. Dis. 2021;7:99. doi: 10.1038/s41531-021-00242-2.", "ArticleIdList": ["10.1038/s41531-021-00242-2", "PMC8593128", "34782640"]}, {"Citation": "Fricova D., Harsanyiova J., Trancikova A.K. Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson\u2019s Disease. Int. J. Mol. Sci. 2020;21:8666. doi: 10.3390/ijms21228666.", "ArticleIdList": ["10.3390/ijms21228666", "PMC7698349", "33212934"]}, {"Citation": "Ruffmann C., Bengoa-Vergniory N., Poggiolini I., Ritchie D., Hu M.T., Alegre-Abarrategui J., Parkkinen L. Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson\u2019s disease. Neuropathol. Appl. Neurobiol. 2018;44:722\u2013736. doi: 10.1111/nan.12486.", "ArticleIdList": ["10.1111/nan.12486", "PMC6282510", "29676021"]}, {"Citation": "Liu W., Lim K.L., Tan E.K. Intestine-derived \u03b1-synuclein initiates and aggravates pathogenesis of Parkinson\u2019s disease in Drosophila. Transl. Neurodegener. 2022;11:44. doi: 10.1186/s40035-022-00318-w.", "ArticleIdList": ["10.1186/s40035-022-00318-w", "PMC9575256", "36253844"]}, {"Citation": "Horsager J., Knudsen K., Sommerauer M. Clinical and imaging evidence of brain-first and body-first Parkinson\u2019s disease. Neurobiol. Dis. 2022;164:105626. doi: 10.1016/j.nbd.2022.105626.", "ArticleIdList": ["10.1016/j.nbd.2022.105626", "35031485"]}, {"Citation": "Macdonald R., Barnes K., Hastings C., Mortiboys H. Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: Can mitochondria be targeted therapeutically? Biochem Soc. Trans. 2018;46:891\u2013909. doi: 10.1042/BST20170501.", "ArticleIdList": ["10.1042/BST20170501", "30026371"]}, {"Citation": "Malpartida A.B., Williamson M., Narendra D.P., Wade-Martins R., Ryan B.J. Mitochondrial Dysfunction and Mitophagy in Parkinson\u2019s Disease: From Mechanism to Therapy. Trends Biochem. Sci. 2021;46:329\u2013343. doi: 10.1016/j.tibs.2020.11.007.", "ArticleIdList": ["10.1016/j.tibs.2020.11.007", "33323315"]}, {"Citation": "Kaur R., Mehan S., Singh S. Understanding multifactorial architecture of Parkinson\u2019s disease: Pathophysiology to management. Neurol. Sci. 2019;40:13\u201323. doi: 10.1007/s10072-018-3585-x.", "ArticleIdList": ["10.1007/s10072-018-3585-x", "30267336"]}, {"Citation": "Charan R.A., Johnson B.N., Zaganelli S., Nardozzi J.D., LaVoie M.J. Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin. Cell Death Dis. 2014;5:e1313. doi: 10.1038/cddis.2014.278.", "ArticleIdList": ["10.1038/cddis.2014.278", "PMC4123072", "24991765"]}, {"Citation": "Drouin-Ouellet J. Mitochondrial complex I deficiency and Parkinson disease. Nat. Rev. Neurosci. 2023;24:193. doi: 10.1038/s41583-023-00676-y.", "ArticleIdList": ["10.1038/s41583-023-00676-y", "36697768"]}, {"Citation": "Chen C., McDonald D., Blain A., Mossman E., Atkin K., Marusich M.F., Capaldi R., Bone L., Smith A., Filby A., et al. Parkinson\u2019s disease neurons exhibit alterations in mitochondrial quality control proteins. NPJ Park. Dis. 2023;9:120. doi: 10.1038/s41531-023-00564-3.", "ArticleIdList": ["10.1038/s41531-023-00564-3", "PMC10409763", "37553379"]}, {"Citation": "Rocha E.M., De Miranda B., Sanders L.H. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease. Neurobiol. Dis. 2018;109:249\u2013257. doi: 10.1016/j.nbd.2017.04.004.", "ArticleIdList": ["10.1016/j.nbd.2017.04.004", "28400134"]}, {"Citation": "O\u2019Hara D.M., Pawar G., Kalia S.K., Kalia L.V. LRRK2 and \u03b1-Synuclein: Distinct or Synergistic Players in Parkinson\u2019s Disease? Front. Neurosci. 2020;14:577. doi: 10.3389/fnins.2020.00577.", "ArticleIdList": ["10.3389/fnins.2020.00577", "PMC7311858", "32625052"]}, {"Citation": "Zanon A., Pramstaller P.P., Hicks A.A., Pichler I. Environmental and Genetic Variables Influencing Mitochondrial Health and Parkinson\u2019s Disease Penetrance. Park. Dis. 2018;2018:8684906. doi: 10.1155/2018/8684906.", "ArticleIdList": ["10.1155/2018/8684906", "PMC5863306", "29707191"]}, {"Citation": "Borsche M., Pereira S.L., Klein C., Gr\u00fcnewald A. Mitochondria and Parkinson\u2019s Disease: Clinical, Molecular, and Translational Aspects. J. Park. Dis. 2021;11:45\u201360. doi: 10.3233/JPD-201981.", "ArticleIdList": ["10.3233/JPD-201981", "PMC7990451", "33074190"]}, {"Citation": "Park J.S., Davis R.L., Sue C.M. Mitochondrial Dysfunction in Parkinson\u2019s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr. Neurol. Neurosci. Rep. 2018;18:21. doi: 10.1007/s11910-018-0829-3.", "ArticleIdList": ["10.1007/s11910-018-0829-3", "PMC5882770", "29616350"]}, {"Citation": "Monzio Compagnoni G., Di Fonzo A., Corti S., Comi G.P., Bresolin N., Masliah E. The Role of Mitochondria in Neurodegenerative Diseases: The Lesson from Alzheimer\u2019s Disease and Parkinson\u2019s Disease. Mol. Neurobiol. 2020;57:2959\u20132980. doi: 10.1007/s12035-020-01926-1.", "ArticleIdList": ["10.1007/s12035-020-01926-1", "PMC9047992", "32445085"]}, {"Citation": "Madsen D.A., Schmidt S.I., Blaabjerg M., Meyer M. Interaction between Parkin and \u03b1-Synuclein in PARK2-Mediated Parkinson\u2019s Disease. Cells. 2021;10:283. doi: 10.3390/cells10020283.", "ArticleIdList": ["10.3390/cells10020283", "PMC7911026", "33572534"]}, {"Citation": "Matheoud D., Sugiura A., Bellemare-Pelletier A., Laplante A., Rondeau C., Chemali M., Fazel A., Bergeron J.J., Trudeau L.E., Burelle Y., et al. Parkinson\u2019s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. 2016;166:314\u2013327. doi: 10.1016/j.cell.2016.05.039.", "ArticleIdList": ["10.1016/j.cell.2016.05.039", "27345367"]}, {"Citation": "Mencke P., Boussaad I., Romano C.D., Kitami T., Linster C.L., Kr\u00fcger R. The Role of DJ-1 in Cellular Metabolism and Pathophysiological Implications for Parkinson\u2019s Disease. Cells. 2021;10:347. doi: 10.3390/cells10020347.", "ArticleIdList": ["10.3390/cells10020347", "PMC7915027", "33562311"]}, {"Citation": "Imberechts D., Kinnart I., Wauters F., Terbeek J., Manders L., Wierda K., Eggermont K., Madeiro R.F., Sue C., Verfaillie C., et al. DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. Brain. 2022;145:4368\u20134384. doi: 10.1093/brain/awac313.", "ArticleIdList": ["10.1093/brain/awac313", "PMC9762950", "36039535"]}, {"Citation": "Ammal Kaidery N., Thomas B. Current perspective of mitochondrial biology in Parkinson\u2019s disease. Neurochem. Int. 2018;117:91\u2013113. doi: 10.1016/j.neuint.2018.03.001.", "ArticleIdList": ["10.1016/j.neuint.2018.03.001", "PMC6027640", "29550604"]}, {"Citation": "Pan T., Kondo S., Le W., Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson\u2019s disease. Brain. 2008;131:1969\u20131978. doi: 10.1093/brain/awm318.", "ArticleIdList": ["10.1093/brain/awm318", "18187492"]}, {"Citation": "Navarro-Romero A., Montpey\u00f3 M., Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson\u2019s Disease. Cells. 2020;9:2399. doi: 10.3390/cells9112399.", "ArticleIdList": ["10.3390/cells9112399", "PMC7692401", "33147750"]}, {"Citation": "Abe T., Kuwahara T. Targeting of Lysosomal Pathway Genes for Parkinson\u2019s Disease Modification: Insights From Cellular and Animal Models. Front. Neurol. 2021;12:681369. doi: 10.3389/fneur.2021.681369.", "ArticleIdList": ["10.3389/fneur.2021.681369", "PMC8236816", "34194386"]}, {"Citation": "Lehtonen \u0160., Sonninen T.M., Wojciechowski S., Goldsteins G., Koistinaho J. Dysfunction of Cellular Proteostasis in Parkinson\u2019s Disease. Front. Neurosci. 2019;13:457. doi: 10.3389/fnins.2019.00457.", "ArticleIdList": ["10.3389/fnins.2019.00457", "PMC6524622", "31133790"]}, {"Citation": "Jackson M.P., Hewitt E.W. Cellular proteostasis: Degradation of misfolded proteins by lysosomes. Essays Biochem. 2016;60:173\u2013180.", "ArticleIdList": ["PMC5065703", "27744333"]}, {"Citation": "Senkevich K., Gan-Or Z. Autophagy lysosomal pathway dysfunction in Parkinson\u2019s disease; evidence from human genetics. Park. Relat. Disord. 2020;73:60\u201371. doi: 10.1016/j.parkreldis.2019.11.015.", "ArticleIdList": ["10.1016/j.parkreldis.2019.11.015", "31761667"]}, {"Citation": "Gan-Or Z., Dion P.A., Rouleau G.A. Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy. 2015;11:1443\u20131457. doi: 10.1080/15548627.2015.1067364.", "ArticleIdList": ["10.1080/15548627.2015.1067364", "PMC4590678", "26207393"]}, {"Citation": "Riboldi G.M., Di Fonzo A.B. GBA, Gaucher Disease, and Parkinson\u2019s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells. 2019;8:364. doi: 10.3390/cells8040364.", "ArticleIdList": ["10.3390/cells8040364", "PMC6523296", "31010158"]}, {"Citation": "Lwin A., Orvisky E., Goker-Alpan O., LaMarca M.E., Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 2004;81:70\u201373. doi: 10.1016/j.ymgme.2003.11.004.", "ArticleIdList": ["10.1016/j.ymgme.2003.11.004", "14728994"]}, {"Citation": "Steger M., Tonelli F., Ito G., Davies P., Trost M., Vetter M., Wachter S., Lorentzen E., Duddy G., Wilson S., et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5:e12813. doi: 10.7554/eLife.12813.", "ArticleIdList": ["10.7554/eLife.12813", "PMC4769169", "26824392"]}, {"Citation": "Orenstein S.J., Kuo S.H., Tasset I., Arias E., Koga H., Fernandez-Carasa I., Cortes E., Honig L.S., Dauer W., Consiglio A., et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 2013;16:394\u2013406. doi: 10.1038/nn.3350.", "ArticleIdList": ["10.1038/nn.3350", "PMC3609872", "23455607"]}, {"Citation": "G\u00f3mez-Suaga P., Fdez E., Ram\u00edrez M.B., Hilfiker S. A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson\u2019s Disease. Park. Dis. 2012;2012:324521. doi: 10.1155/2012/324521.", "ArticleIdList": ["10.1155/2012/324521", "PMC3518055", "23251830"]}, {"Citation": "Teixeira M., Sheta R., Idi W., Oueslati A. Alpha-Synuclein and the Endolysosomal System in Parkinson\u2019s Disease: Guilty by Association. Biomolecules. 2021;11:1333. doi: 10.3390/biom11091333.", "ArticleIdList": ["10.3390/biom11091333", "PMC8472725", "34572546"]}, {"Citation": "Vivekanantham S., Shah S., Dewji R., Dewji A., Khatri C., Ologunde R. Neuroinflammation in Parkinson\u2019s disease: Role in neurodegeneration and tissue repair. Int. J. Neurosci. 2015;125:717\u2013725. doi: 10.3109/00207454.2014.982795.", "ArticleIdList": ["10.3109/00207454.2014.982795", "25364880"]}, {"Citation": "Tansey M.G., Wallings R.L., Houser M.C., Herrick M.K., Keating C.E., Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 2022;22:657\u2013673. doi: 10.1038/s41577-022-00684-6.", "ArticleIdList": ["10.1038/s41577-022-00684-6", "PMC8895080", "35246670"]}, {"Citation": "Qian L., Flood P.M. Microglial cells and Parkinson\u2019s disease. Immunol. Res. 2008;41:155\u2013164. doi: 10.1007/s12026-008-8018-0.", "ArticleIdList": ["10.1007/s12026-008-8018-0", "18512160"]}, {"Citation": "Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol. 2005;76:77\u201398. doi: 10.1016/j.pneurobio.2005.06.004.", "ArticleIdList": ["10.1016/j.pneurobio.2005.06.004", "16081203"]}, {"Citation": "Nakagawa Y., Chiba K. Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals. 2014;7:1028\u20131048. doi: 10.3390/ph7121028.", "ArticleIdList": ["10.3390/ph7121028", "PMC4276905", "25429645"]}, {"Citation": "Butovsky O., Talpalar A.E., Ben-Yaakov K., Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 2005;29:381\u2013393. doi: 10.1016/j.mcn.2005.03.005.", "ArticleIdList": ["10.1016/j.mcn.2005.03.005", "15890528"]}, {"Citation": "Zhou X., Spittau B., Krieglstein K. TGF\u03b2 signalling plays an important role in IL4-induced alternative activation of microglia. J. Neuroinflammation. 2012;9:210. doi: 10.1186/1742-2094-9-210.", "ArticleIdList": ["10.1186/1742-2094-9-210", "PMC3488564", "22947253"]}, {"Citation": "Guo S., Wang H., Yin Y. Microglia Polarization From M1 to M2 in Neurodegenerative Diseases. Front. Aging Neurosci. 2022;14:815347. doi: 10.3389/fnagi.2022.815347.", "ArticleIdList": ["10.3389/fnagi.2022.815347", "PMC8888930", "35250543"]}, {"Citation": "Isik S., Kiyak B.Y., Akbayir R., Seyhali R., Arpaci T. Microglia Mediated Neuroinflammation in Parkinson\u2019s Disease. Cells. 2023;12:1012. doi: 10.3390/cells12071012.", "ArticleIdList": ["10.3390/cells12071012", "PMC10093562", "37048085"]}, {"Citation": "Tang Y., Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol. Neurobiol. 2016;53:1181\u20131194. doi: 10.1007/s12035-014-9070-5.", "ArticleIdList": ["10.1007/s12035-014-9070-5", "25598354"]}, {"Citation": "Jung U.J., Kim S.R. Beneficial Effects of Flavonoids Against Parkinson\u2019s Disease. J. Med. Food. 2018;21:421\u2013432. doi: 10.1089/jmf.2017.4078.", "ArticleIdList": ["10.1089/jmf.2017.4078", "29412767"]}, {"Citation": "Khazdair M.R., Kianmehr M., Anaeigoudari A. Effects of Medicinal Plants and Flavonoids on Parkinson\u2019s Disease: A Review on Basic and Clinical Evidences. Adv. Pharm. Bull. 2021;11:224\u2013232. doi: 10.34172/apb.2021.026.", "ArticleIdList": ["10.34172/apb.2021.026", "PMC8046395", "33880344"]}, {"Citation": "Magalingam K.B., Radhakrishnan A.K., Haleagrahara N. Protective Mechanisms of Flavonoids in Parkinson\u2019s Disease. Oxid. Med. Cell. Longev. 2015;2015:314560. doi: 10.1155/2015/314560.", "ArticleIdList": ["10.1155/2015/314560", "PMC4630416", "26576219"]}, {"Citation": "Chen Y., Peng F., Xing Z., Chen J., Peng C., Li D. Beneficial effects of natural flavonoids on neuroinflammation. Front. Immunol. 2022;13:1006434. doi: 10.3389/fimmu.2022.1006434.", "ArticleIdList": ["10.3389/fimmu.2022.1006434", "PMC9638012", "36353622"]}, {"Citation": "Lu J., Wang J., Yu L., Cui R., Zhang Y., Ding H., Yan G. Shaoyao-Gancao Decoction Promoted Microglia M2 Polarization via the IL-13-Mediated JAK2/STAT6 Pathway to Alleviate Cerebral Ischemia-Reperfusion Injury. Mediat. Inflamm. 2022;2022:1707122. doi: 10.1155/2022/1707122.", "ArticleIdList": ["10.1155/2022/1707122", "PMC9232306", "35757105"]}, {"Citation": "Wang T., Yin Y., Jiang X., Ruan Y., Xu J., Hu X., Li T., Chu L., Li L. Exploring the mechanism of luteolin by regulating microglia polarization based on network pharmacology and in vitro experiments. Sci. Rep. 2023;13:13767. doi: 10.1038/s41598-023-41101-9.", "ArticleIdList": ["10.1038/s41598-023-41101-9", "PMC10447507", "37612462"]}, {"Citation": "Zhang T.T., Xue R., Fan S.Y., Fan Q.Y., An L., Li J., Zhu L., Ran Y.H., Zhang L.M., Zhong B.H., et al. Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord. J. Neuroinflammation. 2018;15:176. doi: 10.1186/s12974-018-1216-3.", "ArticleIdList": ["10.1186/s12974-018-1216-3", "PMC5992688", "29879988"]}, {"Citation": "Heidari A., Yazdanpanah N., Rezaei N. The role of Toll-like receptors and neuroinflammation in Parkinson\u2019s disease. J. Neuroinflammation. 2022;19:135. doi: 10.1186/s12974-022-02496-w.", "ArticleIdList": ["10.1186/s12974-022-02496-w", "PMC9172200", "35668422"]}, {"Citation": "Yun S.P., Kam T.I., Panicker N., Kim S., Oh Y., Park J.S., Kwon S.H., Park Y.J., Karuppagounder S.S., Park H., et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat. Med. 2018;24:931\u2013938. doi: 10.1038/s41591-018-0051-5.", "ArticleIdList": ["10.1038/s41591-018-0051-5", "PMC6039259", "29892066"]}, {"Citation": "Yang C., Mo Y., Xu E., Wen H., Wei R., Li S., Zheng J., Li W., Le B., Chen Y., et al. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson\u2019s disease mouse model. Int. Immunopharmacol. 2019;75:105651. doi: 10.1016/j.intimp.2019.05.036.", "ArticleIdList": ["10.1016/j.intimp.2019.05.036", "31401385"]}, {"Citation": "Maciel-Bar\u00f3n L., Moreno-Blas D., Morales-Rosales S.L., Gonz\u00e1lez-Puertos V.Y., L\u00f3pez-D\u00edazguerrero N.E., Torres C., Castro-Obreg\u00f3n S., K\u00f6nigsberg M. Cellular Senescence, Neurological Function, and Redox State. Antioxid. Redox Signal. 2018;28:1704\u20131723. doi: 10.1089/ars.2017.7112.", "ArticleIdList": ["10.1089/ars.2017.7112", "28467755"]}, {"Citation": "Santoro A., Spinelli C.C., Martucciello S., Nori S.L., Capunzo M., Puca A.A., Ciaglia E. Innate immunity and cellular senescence: The good and the bad in the developmental and aged brain. J. Leukoc. Biol. 2018;103:509\u2013524. doi: 10.1002/JLB.3MR0118-003R.", "ArticleIdList": ["10.1002/JLB.3MR0118-003R", "29389023"]}, {"Citation": "Xia M.L., Xie X.H., Ding J.H., Du R.H., Hu G. Astragaloside IV inhibits astrocyte senescence: Implication in Parkinson\u2019s disease. J. Neuroinflammation. 2020;17:105. doi: 10.1186/s12974-020-01791-8.", "ArticleIdList": ["10.1186/s12974-020-01791-8", "PMC7137443", "32252767"]}, {"Citation": "Dutta D., Jana M., Majumder M., Mondal S., Roy A., Pahan K. Selective targeting of the TLR2/MyD88/NF-\u03baB pathway reduces \u03b1-synuclein spreading in vitro and in vivo. Nat. Commun. 2021;12:5382. doi: 10.1038/s41467-021-25767-1.", "ArticleIdList": ["10.1038/s41467-021-25767-1", "PMC8433339", "34508096"]}, {"Citation": "Ramirez A.I., de Hoz R., Salobrar-Garcia E., Salazar J.J., Rojas B., Ajoy D., L\u00f3pez-Cuenca I., Rojas P., Trivi\u00f1o A., Ram\u00edrez J.M. The Role of Microglia in Retinal Neurodegeneration: Alzheimer\u2019s Disease, Parkinson, and Glaucoma. Front. Aging Neurosci. 2017;9:214. doi: 10.3389/fnagi.2017.00214.", "ArticleIdList": ["10.3389/fnagi.2017.00214", "PMC5498525", "28729832"]}, {"Citation": "Qu Y., Li J., Qin Q., Wang D., Zhao J., An K., Mao Z., Min Z., Xiong Y., Li J., et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease. NPJ Park. Dis. 2023;9:18. doi: 10.1038/s41531-023-00449-5.", "ArticleIdList": ["10.1038/s41531-023-00449-5", "PMC9899271", "36739284"]}, {"Citation": "Gundersen V. Parkinson\u2019s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? Front. Neurosci. 2020;14:580311. doi: 10.3389/fnins.2020.580311.", "ArticleIdList": ["10.3389/fnins.2020.580311", "PMC7946840", "33716638"]}, {"Citation": "Nagatsu T., Sawada M. Inflammatory process in Parkinson\u2019s disease: Role for cytokines. Curr. Pharm. Des. 2005;11:999\u20131016. doi: 10.2174/1381612053381620.", "ArticleIdList": ["10.2174/1381612053381620", "15777250"]}, {"Citation": "Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson\u2019s disease. J. Neuroinflammation. 2008;5:8. doi: 10.1186/1742-2094-5-8.", "ArticleIdList": ["10.1186/1742-2094-5-8", "PMC2292163", "18304357"]}, {"Citation": "de Bie R.M.A., Clarke C.E., Espay A.J., Fox S.H., Lang A.E. Initiation of pharmacological therapy in Parkinson\u2019s disease: When, why, and how. Lancet Neurol. 2020;19:452\u2013461. doi: 10.1016/S1474-4422(20)30036-3.", "ArticleIdList": ["10.1016/S1474-4422(20)30036-3", "32171387"]}, {"Citation": "Ntetsika T., Papathoma P.E., Markaki I. Novel targeted therapies for Parkinson\u2019s disease. Mol. Med. 2021;27:17. doi: 10.1186/s10020-021-00279-2.", "ArticleIdList": ["10.1186/s10020-021-00279-2", "PMC7905684", "33632120"]}, {"Citation": "Carrarini C., Russo M., Dono F., Di Pietro M., Rispoli M.G., Di Stefano V., Ferri L., Barbone F., Vitale M., Thomas A., et al. A Stage-Based Approach to Therapy in Parkinson\u2019s Disease. Biomolecules. 2019;9:388. doi: 10.3390/biom9080388.", "ArticleIdList": ["10.3390/biom9080388", "PMC6723065", "31434341"]}, {"Citation": "Kim S.W., Lee J.H., Kim B., Yang G., Kim J.U. Natural Products as the Potential to Improve Alzheimer\u2019s and Parkinson\u2019s Disease. Int. J. Mol. Sci. 2023;24:8827. doi: 10.3390/ijms24108827.", "ArticleIdList": ["10.3390/ijms24108827", "PMC10218422", "37240173"]}, {"Citation": "Kwon D.K., Kwatra M., Wang J., Ko H.S. Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease: Pathogenesis and Emerging Treatment Strategies. Cells. 2022;11:3736. doi: 10.3390/cells11233736.", "ArticleIdList": ["10.3390/cells11233736", "PMC9736114", "36496996"]}, {"Citation": "Elsworth J.D. Parkinson\u2019s disease treatment: Past, present, and future. J. Neural. Transm. 2020;127:785\u2013791. doi: 10.1007/s00702-020-02167-1.", "ArticleIdList": ["10.1007/s00702-020-02167-1", "PMC8330829", "32172471"]}, {"Citation": "Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson\u2019s disease. Int. Rev. Neurobiol. 2010;95:207\u2013225.", "ArticleIdList": ["21095464"]}, {"Citation": "Tan Y.Y., Jenner P., Chen S.D. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future. J. Park. Dis. 2022;12:477\u2013493. doi: 10.3233/JPD-212976.", "ArticleIdList": ["10.3233/JPD-212976", "PMC8925102", "34957948"]}, {"Citation": "Malek N.M., Grosset D.G. Investigational agents in the treatment of Parkinson\u2019s disease: Focus on safinamide. J. Exp. Pharmacol. 2012;4:85\u201390. doi: 10.2147/JEP.S34343.", "ArticleIdList": ["10.2147/JEP.S34343", "PMC4863549", "27186120"]}, {"Citation": "Jost W.H. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J. Neural. Transm. 2022;129:723\u2013736. doi: 10.1007/s00702-022-02465-w.", "ArticleIdList": ["10.1007/s00702-022-02465-w", "PMC9188534", "35107654"]}, {"Citation": "Borovac J.A. Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology. Yale J. Biol. Med. 2016;89:37\u201347.", "ArticleIdList": ["PMC4797835", "27505015"]}, {"Citation": "Fan S., Yin Q., Li D., Ma J., Li L., Chai S., Guo H., Yang Z. Anti-neuroinflammatory effects of Eucommia ulmoides Oliv. In a Parkinson\u2019s mouse model through the regulation of p38/JNK-Fosl2 gene expression. J. Ethnopharmacol. 2020;260:113016.", "ArticleIdList": ["32464317"]}, {"Citation": "Li L., Fan S., Zhang W., Li D., Yang Z., Zhuang P., Han J., Guo H., Zhang Y. Duzhong Fang Attenuates the POMC-Derived Neuroinflammation in Parkinsonian Mice. J. Inflamm. Res. 2021;14:3261\u20133276. doi: 10.2147/JIR.S316314.", "ArticleIdList": ["10.2147/JIR.S316314", "PMC8315774", "34326654"]}, {"Citation": "Jang M., Lee M.J., Lee J.M., Bae C.S., Kim S.H., Ryu J.H., Cho I.H. Oriental medicine Kyung-Ok-Ko prevents and alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats. PLoS ONE. 2014;9:e87623. doi: 10.1371/journal.pone.0087623.", "ArticleIdList": ["10.1371/journal.pone.0087623", "PMC3919730", "24520334"]}, {"Citation": "Choi J.H., Jang M., Lee J.I., Chung W.S., Cho I.H. Neuroprotective Effects of a Traditional Multi-Herbal Medicine Kyung-Ok-Ko in an Animal Model of Parkinson\u2019s Disease: Inhibition of MAPKs and NF-\u03baB Pathways and Activation of Keap1-Nrf2 Pathway. Front. Pharmacol. 2018;9:1444. doi: 10.3389/fphar.2018.01444.", "ArticleIdList": ["10.3389/fphar.2018.01444", "PMC6300575", "30618742"]}, {"Citation": "Zhang Y., Sun H.M., He X., Wang Y.Y., Gao Y.S., Wu H.X., Xu H., Gong X.G., Guo Z.Y. Da-Bu-Yin-Wan and Qian-Zheng-San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinson\u2019s disease. J. Ethnopharmacol. 2013;146:363\u2013371. doi: 10.1016/j.jep.2013.01.005.", "ArticleIdList": ["10.1016/j.jep.2013.01.005", "23347961"]}, {"Citation": "Zhang Y., XGong G., Sun H.M., Guo Z.Y., Hu J.H., Wang Y.Y., Feng W.D., Li L., Li P., Wang Z.Z., et al. Da-Bu-Yin-Wan Improves the Ameliorative Effect of DJ-1 on Mitochondrial Dysfunction Through Augmenting the Akt Phosphorylation in a Cellular Model of Parkinson\u2019s Disease. Front. Pharmacol. 2018;9:1206. doi: 10.3389/fphar.2018.01206.", "ArticleIdList": ["10.3389/fphar.2018.01206", "PMC6200911", "30405418"]}, {"Citation": "Fenard D., Lambeau G., Maurin T., Lefebvre J.C., Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. 2001;60:341\u2013347. doi: 10.1124/mol.60.2.341.", "ArticleIdList": ["10.1124/mol.60.2.341", "11455021"]}, {"Citation": "Nakashima S., Kitamoto K., Arioka M. The catalytic activity, but not receptor binding, of sPLA2s plays a critical role for neurite outgrowth induction in PC12 cells. Brain Res. 2004;1015:207\u2013211. doi: 10.1016/j.brainres.2004.04.069.", "ArticleIdList": ["10.1016/j.brainres.2004.04.069", "15223389"]}, {"Citation": "Ye M., Chung H.S., Lee C., Song J.H., Shim I., Kim Y.S., Bae H. Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson\u2019s disease alpha-synuclein transgenic mice. Exp. Mol. Med. 2016;48:e244. doi: 10.1038/emm.2016.49.", "ArticleIdList": ["10.1038/emm.2016.49", "PMC4973312", "27388550"]}, {"Citation": "Kiasalari Z., Khalili M., Baluchnejadmojarad T., Roghani M. Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat. Neurochem. Res. 2016;41:1065\u20131072. doi: 10.1007/s11064-015-1796-6.", "ArticleIdList": ["10.1007/s11064-015-1796-6", "26700436"]}, {"Citation": "Zhang B., Yu D., Luo N., Yang C., Zhu Y. Four active monomers from Moutan Cortex exert inhibitory effects against oxidative stress by activating Nrf2/Keap1 signaling pathway. Korean J. Physiol. Pharmacol. 2020;24:373\u2013384. doi: 10.4196/kjpp.2020.24.5.373.", "ArticleIdList": ["10.4196/kjpp.2020.24.5.373", "PMC7445476", "32830144"]}, {"Citation": "Shi X., Chen Y.H., Liu H., Qu H.D. Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson\u2019s disease in mice. Mol. Med. Rep. 2016;14:2397\u20132404. doi: 10.3892/mmr.2016.5573.", "ArticleIdList": ["10.3892/mmr.2016.5573", "PMC4991680", "27484986"]}, {"Citation": "Liu Y., Gao J., Peng M., Meng H., Ma H., Cai P., Xu Y., Zhao Q., Si G. A Review on Central Nervous System Effects of Gastrodin. Front. Pharmacol. 2018;9:24. doi: 10.3389/fphar.2018.00024.", "ArticleIdList": ["10.3389/fphar.2018.00024", "PMC5801292", "29456504"]}, {"Citation": "He J., Li X., Yang S., Li Y., Lin X., Xiu M., Li X., Liu Y. Gastrodin extends the lifespan and protects against neurodegeneration in the Drosophila PINK1 model of Parkinson\u2019s disease. Food Funct. 2021;12:7816\u20137824. doi: 10.1039/D1FO00847A.", "ArticleIdList": ["10.1039/D1FO00847A", "34232246"]}, {"Citation": "Pupyshev A.B., Klyushnik T.P., Akopyan A.A., Singh S.K., Tikhonova M.A. Disaccharide trehalose in experimental therapies for neurodegenerative disorders: Molecular targets and translational potential. Pharmacol. Res. 2022;183:106373. doi: 10.1016/j.phrs.2022.106373.", "ArticleIdList": ["10.1016/j.phrs.2022.106373", "35907433"]}, {"Citation": "Bastin A.R., Nazari-Robati M., Sadeghi H., Doustimotlagh A.H., Sadeghi A. Trehalose and N-Acetyl Cysteine Alleviate Inflammatory Cytokine Production and Oxidative Stress in LPS-Stimulated Human Peripheral Blood Mononuclear Cells. Immunol. Investig. 2022;51:963\u2013979. doi: 10.1080/08820139.2021.1891095.", "ArticleIdList": ["10.1080/08820139.2021.1891095", "33632046"]}, {"Citation": "He Q., Koprich J.B., Wang Y., Yu W.B., Xiao B.G., Brotchie J.M., Wang J. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV \u03b1-Synuclein Rat Model of Parkinson\u2019s Disease. Mol. Neurobiol. 2016;53:2258\u20132268. doi: 10.1007/s12035-015-9173-7.", "ArticleIdList": ["10.1007/s12035-015-9173-7", "25972237"]}, {"Citation": "Law B.Y., Mok S.W., Wu A.G., Lam C.W., Yu M.X., Wong V.K. New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy. Molecules. 2016;21:359. doi: 10.3390/molecules21030359.", "ArticleIdList": ["10.3390/molecules21030359", "PMC6274228", "26999089"]}, {"Citation": "Chang W.H., Chen C.H., Lu F.J. Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines. Planta Med. 2002;68:128\u2013132. doi: 10.1055/s-2002-20246.", "ArticleIdList": ["10.1055/s-2002-20246", "11859462"]}, {"Citation": "Liu C., Huang X., Qiu S., Chen W., Li W., Zhang H., Wang T., Wang X., Wu X. Chinese Herbal Complex \u2018Bu Shen Jie Du Fang\u2019 (BSJDF) Modulated Autophagy in an MPP(+)-Induced Cell Model of Parkinson\u2019s Disease. Evid. Based Complement Altern. Med. 2019;2019:8920813. doi: 10.1155/2019/8920813.", "ArticleIdList": ["10.1155/2019/8920813", "PMC6436328", "31001356"]}, {"Citation": "Nogueira Neto J.D., de Almeida A.A., da Silva Oliveira J., Santos P.S.D., de Sousa D.P., de Freitas R.M. Antioxidant effects of nerolidol in mice hippocampus after open field test. Neurochem. Res. 2013;38:1861\u20131870. doi: 10.1007/s11064-013-1092-2.", "ArticleIdList": ["10.1007/s11064-013-1092-2", "23765368"]}, {"Citation": "Javed H., Azimullah S., Khair S.B.A., Ojha S., Haque M.E. Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone. BMC Neurosci. 2016;17:58. doi: 10.1186/s12868-016-0293-4.", "ArticleIdList": ["10.1186/s12868-016-0293-4", "PMC4994214", "27549180"]}, {"Citation": "Ingole A., Kadam M.P., Dalu A.P., Kute S.M., Mange P.R., Theng V.D., Lahane O.R., Nikas A.P., Kawal Y.V., Nagrik S.U., et al. A review of the pharmacological characteristics of vanillic acid. J. Drug Deliv. Ther. 2021;11:200\u2013204. doi: 10.22270/jddt.v11i2-S.4823.", "ArticleIdList": ["10.22270/jddt.v11i2-S.4823"]}, {"Citation": "Lu C., Qu S., Zhong Z., Luo H., Lei S.S., Zhong H.J., Su H., Wang Y., Chong C.M. The effects of bioactive components from the rhizome of gastrodia elata blume (Tianma) on the characteristics of Parkinson\u2019s disease. Front. Pharmacol. 2022;13:963327. doi: 10.3389/fphar.2022.963327.", "ArticleIdList": ["10.3389/fphar.2022.963327", "PMC9748092", "36532787"]}, {"Citation": "Abuthawabeh R., Abuirmeileh A.N., Alzoubi K.H. The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson\u2019s disease. Restor. Neurol. Neurosci. 2020;38:369\u2013373. doi: 10.3233/RNN-201028.", "ArticleIdList": ["10.3233/RNN-201028", "32986633"]}, {"Citation": "Petramfar P., Hajari F., Yousefi G., Azadi S., Hamedi A. Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson\u2019s disease, A randomized double blinded clinical trial. J. Ethnopharmacol. 2020;247:112226. doi: 10.1016/j.jep.2019.112226.", "ArticleIdList": ["10.1016/j.jep.2019.112226", "31574343"]}, {"Citation": "Zargaran A., Zarshenas M.M., Mehdizadeh A., Mohagheghzadeh A. Management of tremor in medieval Persia. J. Hist Neurosci. 2013;22:53\u201361. doi: 10.1080/0964704X.2012.670475.", "ArticleIdList": ["10.1080/0964704X.2012.670475", "23323532"]}, {"Citation": "Chin Y.W., Jung H.A., Liu Y., Su B.N., Castoro J.A., Keller W.J., Pereira M.A., Kinghorn A.D. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra) J. Agric. Food Chem. 2007;55:4691\u20134697. doi: 10.1021/jf0703553.", "ArticleIdList": ["10.1021/jf0703553", "17516657"]}, {"Citation": "Sheela M.L., Ramakrishna M.K., Salimath B.P. Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by Glycyrrhiza glabra. Int. Immunopharmacol. 2006;6:494\u2013498. doi: 10.1016/j.intimp.2005.07.002.", "ArticleIdList": ["10.1016/j.intimp.2005.07.002", "16428085"]}, {"Citation": "Dhingra D., Sharma A. Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006;30:449\u2013454. doi: 10.1016/j.pnpbp.2005.11.019.", "ArticleIdList": ["10.1016/j.pnpbp.2005.11.019", "16443316"]}, {"Citation": "Dhingra D., Parle M., Kulkarni S.K. Memory enhancing activity of Glycyrrhiza glabra in mice. J. Ethnopharmacol. 2004;91:361\u2013365. doi: 10.1016/j.jep.2004.01.016.", "ArticleIdList": ["10.1016/j.jep.2004.01.016", "15120462"]}, {"Citation": "Yu X.Q., Xue C.C., Zhou Z.W., Li C.G., Du Y.M., Liang J., Zhou S.F. In vitro and in vivo neuroprotective effect and mechanisms of glabridin, a major active isoflavan from Glycyrrhiza glabra (licorice) Life Sci. 2008;82:68\u201378. doi: 10.1016/j.lfs.2007.10.019.", "ArticleIdList": ["10.1016/j.lfs.2007.10.019", "18048062"]}, {"Citation": "Chahra C., Anis H., Bissene D., Mejda S., Jih\u00e8ne M., Salma N., Manel N., Sana B.A., Hedi K., Maha B.F. The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson\u2019s disease: A randomized controlled pilot study. Park. Relat. Disord. 2021;91:23\u201327. doi: 10.1016/j.parkreldis.2021.08.013.", "ArticleIdList": ["10.1016/j.parkreldis.2021.08.013", "34455218"]}, {"Citation": "Gu S.C., Ye Q., Wang C.D., Zhao S.R., Zhou J., Gao C., Zhang Y., Liu Z.G., Yuan C.X. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson\u2019s Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Front. Pharmacol. 2022;13:739194.", "ArticleIdList": ["PMC8914044", "35281890"]}, {"Citation": "Beitz J.M. Parkinson\u2019s disease: A review. Front. Biosci. (Schol. Ed.) 2014;6:65\u201374. doi: 10.2741/S415.", "ArticleIdList": ["10.2741/S415", "24389262"]}, {"Citation": "Radhakrishnan D.M., Goyal V. Parkinson\u2019s disease: A review. Neurol. India. 2018;66:S26\u2013S35.", "ArticleIdList": ["29503325"]}, {"Citation": "Mullin S., Schapira A. \u03b1-Synuclein and mitochondrial dysfunction in Parkinson\u2019s disease. Mol. Neurobiol. 2013;47:587\u2013597. doi: 10.1007/s12035-013-8394-x.", "ArticleIdList": ["10.1007/s12035-013-8394-x", "PMC4199090", "23361255"]}, {"Citation": "Mazzulli J.R., Zunke F., Isacson O., Studer L., Krainc D. \u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc. Natl. Acad. Sci. USA. 2016;113:1931\u20131936. doi: 10.1073/pnas.1520335113.", "ArticleIdList": ["10.1073/pnas.1520335113", "PMC4763774", "26839413"]}, {"Citation": "La Vitola P., Balducci C., Baroni M., Artioli L., Santamaria G., Castiglioni M., Cerovic M., Colombo L., Caldinelli L., Pollegioni L., et al. Peripheral inflammation exacerbates \u03b1-synuclein toxicity and neuropathology in Parkinson\u2019s models. Neuropathol. Appl. Neurobiol. 2021;47:43\u201360. doi: 10.1111/nan.12644.", "ArticleIdList": ["10.1111/nan.12644", "32696999"]}, {"Citation": "Jankovic J., Aguilar L.G. Current approaches to the treatment of Parkinson\u2019s disease. Neuropsychiatr. Dis. Treat. 2008;4:743\u2013757. doi: 10.2147/NDT.S2006.", "ArticleIdList": ["10.2147/NDT.S2006", "PMC2536542", "19043519"]}, {"Citation": "Jankovic J., Tan E.K. Parkinson\u2019s disease: Etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry. 2020;91:795\u2013808. doi: 10.1136/jnnp-2019-322338.", "ArticleIdList": ["10.1136/jnnp-2019-322338", "32576618"]}, {"Citation": "Koeberle A., Werz O. Multi-target approach for natural products in inflammation. Drug Discov. Today. 2014;19:1871\u20131882. doi: 10.1016/j.drudis.2014.08.006.", "ArticleIdList": ["10.1016/j.drudis.2014.08.006", "25172801"]}, {"Citation": "Yang Y., Zhang Z., Li S., Ye X., Li X., He K. Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. Fitoterapia. 2014;92:133\u2013147. doi: 10.1016/j.fitote.2013.10.010.", "ArticleIdList": ["10.1016/j.fitote.2013.10.010", "24177191"]}, {"Citation": "David B., Wolfender J.-L., Dias D.A. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem. Rev. 2015;14:299\u2013315. doi: 10.1007/s11101-014-9367-z.", "ArticleIdList": ["10.1007/s11101-014-9367-z"]}, {"Citation": "Zhou X., Seto S.W., Chang D., Kiat H., Razmovski-Naumovski V., Chan K., Bensoussan A. Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. Front. Pharmacol. 2016;7:201. doi: 10.3389/fphar.2016.00201.", "ArticleIdList": ["10.3389/fphar.2016.00201", "PMC4940614", "27462269"]}, {"Citation": "Thomford N.E., Senthebane D.A., Rowe A., Munro D., Seele P., Maroyi A., Dzobo K. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci. 2018;19:1578. doi: 10.3390/ijms19061578.", "ArticleIdList": ["10.3390/ijms19061578", "PMC6032166", "29799486"]}]}], "History": [{"Year": "2023", "Month": "11", "Day": "22"}, {"Year": "2024", "Month": "1", "Day": "9"}, {"Year": "2024", "Month": "1", "Day": "12"}, {"Year": "2024", "Month": "1", "Day": "24", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "23", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "1", "Day": "23", "Hour": "1", "Minute": "12"}, {"Year": "2024", "Month": "1", "Day": "15"}], "PublicationStatus": "epublish", "ArticleIdList": ["38256144", "PMC10816678", "10.3390/ijms25021071", "ijms25021071"]}}]}